MedTrace Logo

iLink (Incentives for Linkage to ART) Study: A Mixed-methods Study to Improve Linkage to HIV Care

NCT02440386 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2016-10-17

No results posted yet for this study

Summary

The iLink Study examines whether a Conditional Economic Incentive (CEI) may be an effective tool for improving linkage to HIV treatment and care following referral for antiretroviral therapy (ART) services from a mobile health clinic in Cape Town, South Africa. The study examines the feasibility and acceptability of using a R300 (approximately $25 as of April 2015) voucher - that is exchanged for cash upon initiation of ART within 3 months - to increase the uptake of ART among men and women living in low-income areas. This pilot study (n=64) includes a randomised control trial, follow-up telephone calls and medical record reviews, and in-depth interviews.

Conditions

Interventions

BEHAVIORAL

Conditional economic incentive

Individuals in the intervention arm will receive the standard of care. In addition, individuals in the intervention arm receive a voucher worth R300. They are told that they will get this money if they: 1. Initiate ART at any clinic within 3 months from the time of their CD4 count test at the Tutu Tester; and 2. send a text message to the study team to let us know they have started ART; 3. Schedule a meeting with a member of the study team to show their clinic card and ARVs to confirm ART initiation.

Sponsors & Collaborators

  • Brown University

    collaborator OTHER

  • University of Cape Town

    lead OTHER

Principal Investigators

  • Brendan Maughan-Brown, PhD · University of Cape Town

  • Omar Galarraga, PhD · Brown University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-07-31
Completion
2016-11-30

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02440386 on ClinicalTrials.gov